ES2135249T3 - Receptor huerfano. - Google Patents

Receptor huerfano.

Info

Publication number
ES2135249T3
ES2135249T3 ES96931047T ES96931047T ES2135249T3 ES 2135249 T3 ES2135249 T3 ES 2135249T3 ES 96931047 T ES96931047 T ES 96931047T ES 96931047 T ES96931047 T ES 96931047T ES 2135249 T3 ES2135249 T3 ES 2135249T3
Authority
ES
Spain
Prior art keywords
amino acid
acid sequence
receiver
effects
refers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96931047T
Other languages
English (en)
Other versions
ES2135249T5 (es
Inventor
George G J M Kuiper
Eva Enmark
Jan-Ake Gustafsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karo Healthcare AB
Original Assignee
Karo Bio AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2135249(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9518272.1A external-priority patent/GB9518272D0/en
Priority claimed from GBGB9605550.4A external-priority patent/GB9605550D0/en
Priority claimed from GBGB9607532.0A external-priority patent/GB9607532D0/en
Priority claimed from GBGB9609576.5A external-priority patent/GB9609576D0/en
Application filed by Karo Bio AB filed Critical Karo Bio AB
Application granted granted Critical
Publication of ES2135249T3 publication Critical patent/ES2135249T3/es
Publication of ES2135249T5 publication Critical patent/ES2135249T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

ESTA INVENCION SE REFIERE A UN NUEVO RECEPTOR NUCLEAR RELACIONADO CON EL RECEPTOR DE ESTROGENO, DE AHORA EN ADELANTE LLAMADO "ER{BE}" QUE TIENE LA SECUENCIA DE AMINOACIDO DE LAS FIGS. 1, 13A O 14A O SUSTANCIALMENTE LA MISMA SECUENCIA DE AMINOACIDO QUE LA SECUENCIA DE AMINOACIDO MOSTRADA EN LAS FIGS. 1, 13A O 13B O UNA FUNCIONALIDAD DE SECUENCIA DE AMINOACIDO SIMILAR A ESA SECUENCIA. LA INVENCION TAMBIEN SE REFIERE A SECUENCIA DE ADN QUE CODIFICAN EL RECEPTOR. EL RECEPTOR PUEDE SER UTIL EN EL AISLAMIENTO DE MOLECULAS PARA EL TRATAMIENTO DE TRASTORNOS COMO CANCER DE PROSTATA, HIPERPLASIA PROTATICA BENIGNA, OSTEOPOROSIS O TRASTORNOS CARDIOVASCULARES Y EN LA COMPROBACION DE EFECTOS ESTROGENOS Y OTROS EFECTOS HORMONALES EN SUSTANCIAS.
ES96931047T 1995-09-08 1996-09-09 Receptor de estrogenos. Expired - Lifetime ES2135249T5 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GBGB9518272.1A GB9518272D0 (en) 1995-09-08 1995-09-08 Orphan receptor
GB9518272 1995-09-08
GBGB9605550.4A GB9605550D0 (en) 1996-03-15 1996-03-15 Orphan receptor
GB9605550 1996-03-15
GB9607532 1996-04-11
GBGB9607532.0A GB9607532D0 (en) 1996-04-11 1996-04-11 Orphan receptor
GBGB9609576.5A GB9609576D0 (en) 1996-05-08 1996-05-08 Orphan receptor
GB9609576 1996-05-08

Publications (2)

Publication Number Publication Date
ES2135249T3 true ES2135249T3 (es) 1999-10-16
ES2135249T5 ES2135249T5 (es) 2009-09-10

Family

ID=27451339

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96931047T Expired - Lifetime ES2135249T5 (es) 1995-09-08 1996-09-09 Receptor de estrogenos.

Country Status (12)

Country Link
US (2) US5958710A (es)
EP (2) EP0792292B2 (es)
JP (4) JP3131649B2 (es)
KR (1) KR100263137B1 (es)
AT (1) ATE183516T1 (es)
AU (1) AU715528B2 (es)
CA (1) CA2201098C (es)
DE (2) DE792292T1 (es)
DK (1) DK0792292T4 (es)
ES (1) ES2135249T5 (es)
GR (2) GR980300029T1 (es)
WO (1) WO1997009348A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2200423C (en) * 1996-03-26 2006-12-19 Sietse Mosselman Novel estrogen receptor
EP0866127A3 (en) * 1997-03-17 1999-12-22 Smithkline Beecham Plc HE8AN36, a steroid hormone receptor homolog
KR20010013631A (ko) * 1997-06-10 2001-02-26 오테스코그 페르 에스트로겐 수용체 리간드
US7157568B1 (en) 1997-08-05 2007-01-02 American Home Products Corporation Human estrogen receptor-β
US6222015B1 (en) 1997-09-08 2001-04-24 Merck & Co., Inc. Estrogen receptor
ATE335820T1 (de) * 1997-09-08 2006-09-15 Merck & Co Inc Östrogenrezeptor
GB9814620D0 (en) * 1998-07-06 1998-09-02 Karobio Ab Vasculoprotector
DE19839115A1 (de) * 1998-08-27 2000-03-09 Ihf Inst Fuer Hormon Und Fortp Klonierung und Expression von Rinder Estrogenrezeptor-beta
EP1400810A3 (en) * 1999-04-09 2005-03-02 Karo Bio Ab Estrogen receptors and bone disease
DK1165184T3 (da) * 1999-04-09 2004-04-13 Karobio Ab Estrogenreceptor-beta antagonisme og knoglesygdomme
WO2002064783A2 (en) * 2001-02-09 2002-08-22 Lion Bioscience Ag Novel cofactors of the estrogen receptor beta and methods of use
WO2002070697A1 (en) * 2001-03-02 2002-09-12 Lion Bioscience Ag Mammalian nuclear receptor l67 and methods of use
CA2448235A1 (en) 2001-07-31 2003-02-13 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
EA007382B1 (ru) 2001-11-19 2006-10-27 Эли Лилли Энд Компани Замещенные бензопираны в качестве селективных агонистов бета-рецептора эстрогена
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
AU2002353076A1 (en) * 2001-12-07 2003-06-23 Isis Pharmaceuticals, Inc. Antisense modulation of estrogen receptor beta expression
CA2365811A1 (en) * 2001-12-21 2003-06-21 Institut De Cardiologie A new gene therapy using antisense strategy to estrogen receptors (er .alpha. and/or er .beta.) to optimize vascular healing and cardioprotection after vascular injury
JP2006506445A (ja) 2002-08-28 2006-02-23 ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド 治療処置の方法
ES2427626T3 (es) 2003-02-21 2013-10-31 Styron Europe Gmbh Procedimiento para homo- o copolimerización de olefinas conjugadas
CN100374444C (zh) 2003-04-21 2008-03-12 伊莱利利公司 作为选择性β-雌激素受体激动剂的取代的苯并吡喃化合物
ATE457308T1 (de) 2003-04-21 2010-02-15 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
MXPA06001094A (es) 2003-07-28 2006-04-11 Smithkline Beecham Corp Compuestos quimicos.
US20050186645A1 (en) * 2003-12-18 2005-08-25 Yehudit Amor Method for analyzing a glycomolecule
BRPI0514974A (pt) 2004-09-07 2008-07-01 Wyeth Corp composto, composição, métodos de tratar ou inibir uma doença ou condição, estados de doença induzidos por radical livre em um mamìfero, dano à junta secundário aos procedimentos artroscópicos ou cirúrgicos em um mamìfero, infertilidade em um mamìfero, de diminuir os nìveis de colesterol, triglicerìdeos, lp(a), ou ldl, de fornecer realce na cognição ou neuroproteção, de contracepção em um mamìfero, e para preparar um composto, e, produto
GB0704407D0 (en) 2007-03-07 2007-04-18 Glaxo Group Ltd Compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5217867A (en) * 1988-11-30 1993-06-08 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5262300A (en) * 1988-11-30 1993-11-16 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5602009A (en) * 1988-12-23 1997-02-11 The Salk Institute For Biological Studies Dominant negative chimeras of the steroid/thyroid superfamily of receptors
US5597693A (en) * 1989-03-17 1997-01-28 The Salk Institute For Biological Studies Hormone response element compositions and assay
US5438126A (en) * 1989-09-11 1995-08-01 Arch Development Corporation Human thyroid hormone receptor DNA
WO1995013373A1 (en) * 1993-11-10 1995-05-18 Arch Development Corporation Ubiquitous nuclear receptor: compositions and methods
CA2200423C (en) * 1996-03-26 2006-12-19 Sietse Mosselman Novel estrogen receptor

Also Published As

Publication number Publication date
DK0792292T3 (da) 2000-02-07
EP0792292A2 (en) 1997-09-03
US20030113803A1 (en) 2003-06-19
ES2135249T5 (es) 2009-09-10
JP2002010788A (ja) 2002-01-15
DK0792292T4 (da) 2009-07-20
US7132261B2 (en) 2006-11-07
ATE183516T1 (de) 1999-09-15
EP0935000A3 (en) 1999-09-08
WO1997009348A3 (en) 1997-04-24
WO1997009348A2 (en) 1997-03-13
AU6988096A (en) 1997-03-27
EP0935000A2 (en) 1999-08-11
EP0792292B1 (en) 1999-08-18
JP2005204667A (ja) 2005-08-04
JP3131649B2 (ja) 2001-02-05
GR980300029T1 (en) 1998-04-30
CA2201098C (en) 2001-03-27
US5958710A (en) 1999-09-28
JP2005204666A (ja) 2005-08-04
DE69603827T2 (de) 2000-02-24
AU715528B2 (en) 2000-02-03
EP0792292B2 (en) 2009-04-15
JPH11502417A (ja) 1999-03-02
GR3031618T3 (en) 2000-01-31
DE69603827T3 (de) 2009-11-05
CA2201098A1 (en) 1997-03-13
DE69603827D1 (de) 1999-09-23
DE792292T1 (de) 1998-09-03
KR100263137B1 (ko) 2000-08-01

Similar Documents

Publication Publication Date Title
AR030760A1 (es) Nuevos acidos y polipeptidos nucleicos receptores
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
CL2004001852A1 (es) Parche transdermico, formulacion oral y formulacion parenteral que comprenden estrogeno; uso para tratar uno o mas de: osteoporosis, dolores de cabeza, nausea, depresion, calores repentinos, decrecimiento en densidad de minerales en hueso y riesgo o
DK1955700T3 (da) Terapeutisk behandling af androgenreceptor-betingede lidelser
BR0114630A (pt) Secretagogos de hormÈnio do crescimento
ATE294595T1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
EA200100573A1 (ru) Применение ингибитора циклооксигеназы-2, ингибитора матричной металлопротеиназы, противоопухолевого лекарственного средства и факультативно облучения в качестве комбинированного способа лечения неоплазии
EA200300026A1 (ru) Аналоги глюкагоноподобного пептида-1
ATE413386T1 (de) Ppar-gamma modulatoren
PT918774E (pt) Compostos moduladores do receptor para androgenio e metodos
DK0792292T3 (da) Orphan-receptor
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
EP1034188A4 (en) METHOD FOR DESIGNING AGONISTS AND ANTAGONISTS OF THE IGF RECEPTOR
EA200001193A1 (ru) 2-фенил-1-[4-(2-аминоэтокси)бензил]индол в комбинации с эстрогенами
BR0105457A (pt) Combinações terapêuticas para estimulação do crescimento ósseo
YU41998A (sh) Tetrahidrobetakarbolinska jedinjenja
DE60025639D1 (de) Substituierte diazepan
BR9813996A (pt) 2-arilbenzo[b]tiofenos úteis para o tratamento de sìndrome da privação de estrogênio
MXPA03011270A (es) Uso de antagonistas rank para tratar cancer.
GT199800081A (es) Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg coa reductasa para el tratamiento delcancer.
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
ES2100051T3 (es) Sintesis de bloques dimeros y su uso en el ensamblaje de oligonucleotidos.
IS2254B (is) Meðhöndlun á risaeitlingasarkmeini með tálmum viðeitilfrumueiturslóðinni
ES2188936T3 (es) Antagonistas del receptor alfa-q-adrenergico.
TR200000903T2 (tr) Romatizmal arteritlerin tedavisine yönelik yöntem ve kompozisyonlar.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 792292

Country of ref document: ES